Table 2:
Incidence rate (per 100,000 person-years) of IPD stratified by years and age groups.
| Pre-PCV13, 2002–2010 | Post-PCV13, 2011–2018 | p-value compared the two time periods | |||
|---|---|---|---|---|---|
|
| |||||
| Number of cases | Rate (95% CI) | Number of cases | Rate (95% CI) | ||
|
| |||||
| Overall, rates are age- and sex-adjusted b | 115 | 11.1 (9.1, 13.2) | 72 | 5.6 (4.3, 6.9) | <.001 |
| By gender, rates are age-adjusted b | |||||
| Female | 56 | 10.1 (7.4, 12.7) | 34 | 4.9 (3.2, 6.5) | .01 |
| Male | 59 | 12.2 (9.1, 15.4) | 38 | 6.5 (4.4, 8.6) | .01 |
| By age group (years) | |||||
| <5 | 11 | 12.3 (6.2, 22.1) | 6 | 6.6 (2.4, 14.3) | .21 |
| 5–18 | 6 | 2.7 (1.0, 6.0) | 3 | 1.3 (0.3, 3.8) | .30 |
| 19–50 | 20 | 3.7 (2.3, 5.7) | 9 | 1.7 (0.8, 3.2) | .04 |
| 51–64 | 26 | 15.9 (10.4, 23.3) | 12 | 5.5 (2.8, 9.5) | .01 |
| 65+ | 52 | 40.9 (30.5, 53.6) | 42 | 24.6 (17.7, 33.2) | .10 |
a
Abbreviation: CI, confidence interval; IPD, invasive pneumococcal disease; PCV-13, 13-valent pneumococcal conjugate vaccine
b
Adjusted to the population structure of the U.S. total population in 2010.